Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]Citation formats

  • External authors:
  • S Ogden
  • LF Cotterell
  • JJ Bowden
  • JY Bastrilles
  • SP Long

Standard

Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected] : a double‐blind, randomized controlled trial. / Watson, RE; Ogden, S; Cotterell, LF; Bowden, JJ; Bastrilles, JY; Long, SP; Griffiths, CE.

In: British Journal of Dermatology, Vol. 161, No. 2, 08.2009, p. 419-426.

Research output: Contribution to journalArticlepeer-review

Harvard

Watson, RE, Ogden, S, Cotterell, LF, Bowden, JJ, Bastrilles, JY, Long, SP & Griffiths, CE 2009, 'Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]: a double‐blind, randomized controlled trial', British Journal of Dermatology, vol. 161, no. 2, pp. 419-426. https://doi.org/10.1111/j.1365-2133.2009.09216.x

APA

Vancouver

Watson RE, Ogden S, Cotterell LF, Bowden JJ, Bastrilles JY, Long SP et al. Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]: a double‐blind, randomized controlled trial. British Journal of Dermatology. 2009 Aug;161(2):419-426. https://doi.org/10.1111/j.1365-2133.2009.09216.x

Author

Watson, RE ; Ogden, S ; Cotterell, LF ; Bowden, JJ ; Bastrilles, JY ; Long, SP ; Griffiths, CE. / Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected] : a double‐blind, randomized controlled trial. In: British Journal of Dermatology. 2009 ; Vol. 161, No. 2. pp. 419-426.

Bibtex

@article{4be6ed3db63345909a95edf3edadf7ad,
title = "Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]: a double‐blind, randomized controlled trial",
abstract = "Methods For the patch test, commercially available test product and its vehicle were applied occluded for 12-days to photoaged forearm skin (n = 10) prior to biopsy and immunohistochemical assessment of fibrillin-1; all-trans retinoic acid (RA) was used as a positive control. Sixty photoaged subjects were recruited to the RCT (test product, n = 30 vs. vehicle, n = 30; once daily for 6-months; face & hands) with clinical assessments performed at recruitment and following 1-, 3- & 6-months of use. Twenty-eight subjects had skin biopsies (dorsal wrist) at baseline and at 6 months of treatment for immunohistochemical assessment of fibrillin-1 (test product, n = 15; vehicle, n = 13). All subjects received test product for a further 6-months. Final clinical assessments were performed at the end of this open period; 27 subjects received test product for 12-months. Results In the 12-day patch test assay, we observed significant immunohistological deposition of fibrillin-1 in skin treated by test product and RA as compared to untreated baseline (P = 0{\AE}005 and 0{\AE}015 respectively). In the clinical RCT, at 6 months, compared to baseline assessment, 43% of subjects on test product had an improvement in facial wrinkles (P = 0{\AE}013), whereas only 22% of subjects using vehicle had clinical improvement (P = ns). Between group comparison of test product and vehicle was non-significant (P = 0{\AE}10). After 12 months, there was a significant benefit of test product over that projected for vehicle (70% vs. 33% of subjects improving; combined Wilcoxon rank tests, P = 0{\AE}026). There was significant deposition of fibrillin-1 in skin treated for 6 months with test product (mean ± SE; vehicle, 1{\AE}84 ± 0{\AE}23; test product, 2{\AE}57 ± 0{\AE}19; P = 0{\AE}019). Conclusion An over-the-counter cosmetic 'anti-ageing' product demonstrated clear benefit over vehicle in fibrillin-1 deposition over a 6-month trial period. There was a corresponding but non-significant trend towards clinical improvement in facial wrinkles. Clinical improvements in the treated group were increased after a further 6-months of use. This study demonstrates that a cosmetic may improve the appearance of wrinkles and further supports the use of fibrillin-1 as a robust biomarker for repair of photoaged dermis.",
keywords = "Fibrillin-1, Patch-test assay, Randomized controlled trial, Wrinkles",
author = "RE Watson and S Ogden and LF Cotterell and JJ Bowden and JY Bastrilles and SP Long and CE Griffiths",
year = "2009",
month = aug,
doi = "10.1111/j.1365-2133.2009.09216.x",
language = "English",
volume = "161",
pages = "419--426",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "John Wiley & Sons Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Effects of a cosmetic 'anti-ageing' product improves photoaged skin [corrected]

T2 - a double‐blind, randomized controlled trial

AU - Watson, RE

AU - Ogden, S

AU - Cotterell, LF

AU - Bowden, JJ

AU - Bastrilles, JY

AU - Long, SP

AU - Griffiths, CE

PY - 2009/8

Y1 - 2009/8

N2 - Methods For the patch test, commercially available test product and its vehicle were applied occluded for 12-days to photoaged forearm skin (n = 10) prior to biopsy and immunohistochemical assessment of fibrillin-1; all-trans retinoic acid (RA) was used as a positive control. Sixty photoaged subjects were recruited to the RCT (test product, n = 30 vs. vehicle, n = 30; once daily for 6-months; face & hands) with clinical assessments performed at recruitment and following 1-, 3- & 6-months of use. Twenty-eight subjects had skin biopsies (dorsal wrist) at baseline and at 6 months of treatment for immunohistochemical assessment of fibrillin-1 (test product, n = 15; vehicle, n = 13). All subjects received test product for a further 6-months. Final clinical assessments were performed at the end of this open period; 27 subjects received test product for 12-months. Results In the 12-day patch test assay, we observed significant immunohistological deposition of fibrillin-1 in skin treated by test product and RA as compared to untreated baseline (P = 0Æ005 and 0Æ015 respectively). In the clinical RCT, at 6 months, compared to baseline assessment, 43% of subjects on test product had an improvement in facial wrinkles (P = 0Æ013), whereas only 22% of subjects using vehicle had clinical improvement (P = ns). Between group comparison of test product and vehicle was non-significant (P = 0Æ10). After 12 months, there was a significant benefit of test product over that projected for vehicle (70% vs. 33% of subjects improving; combined Wilcoxon rank tests, P = 0Æ026). There was significant deposition of fibrillin-1 in skin treated for 6 months with test product (mean ± SE; vehicle, 1Æ84 ± 0Æ23; test product, 2Æ57 ± 0Æ19; P = 0Æ019). Conclusion An over-the-counter cosmetic 'anti-ageing' product demonstrated clear benefit over vehicle in fibrillin-1 deposition over a 6-month trial period. There was a corresponding but non-significant trend towards clinical improvement in facial wrinkles. Clinical improvements in the treated group were increased after a further 6-months of use. This study demonstrates that a cosmetic may improve the appearance of wrinkles and further supports the use of fibrillin-1 as a robust biomarker for repair of photoaged dermis.

AB - Methods For the patch test, commercially available test product and its vehicle were applied occluded for 12-days to photoaged forearm skin (n = 10) prior to biopsy and immunohistochemical assessment of fibrillin-1; all-trans retinoic acid (RA) was used as a positive control. Sixty photoaged subjects were recruited to the RCT (test product, n = 30 vs. vehicle, n = 30; once daily for 6-months; face & hands) with clinical assessments performed at recruitment and following 1-, 3- & 6-months of use. Twenty-eight subjects had skin biopsies (dorsal wrist) at baseline and at 6 months of treatment for immunohistochemical assessment of fibrillin-1 (test product, n = 15; vehicle, n = 13). All subjects received test product for a further 6-months. Final clinical assessments were performed at the end of this open period; 27 subjects received test product for 12-months. Results In the 12-day patch test assay, we observed significant immunohistological deposition of fibrillin-1 in skin treated by test product and RA as compared to untreated baseline (P = 0Æ005 and 0Æ015 respectively). In the clinical RCT, at 6 months, compared to baseline assessment, 43% of subjects on test product had an improvement in facial wrinkles (P = 0Æ013), whereas only 22% of subjects using vehicle had clinical improvement (P = ns). Between group comparison of test product and vehicle was non-significant (P = 0Æ10). After 12 months, there was a significant benefit of test product over that projected for vehicle (70% vs. 33% of subjects improving; combined Wilcoxon rank tests, P = 0Æ026). There was significant deposition of fibrillin-1 in skin treated for 6 months with test product (mean ± SE; vehicle, 1Æ84 ± 0Æ23; test product, 2Æ57 ± 0Æ19; P = 0Æ019). Conclusion An over-the-counter cosmetic 'anti-ageing' product demonstrated clear benefit over vehicle in fibrillin-1 deposition over a 6-month trial period. There was a corresponding but non-significant trend towards clinical improvement in facial wrinkles. Clinical improvements in the treated group were increased after a further 6-months of use. This study demonstrates that a cosmetic may improve the appearance of wrinkles and further supports the use of fibrillin-1 as a robust biomarker for repair of photoaged dermis.

KW - Fibrillin-1

KW - Patch-test assay

KW - Randomized controlled trial

KW - Wrinkles

U2 - 10.1111/j.1365-2133.2009.09216.x

DO - 10.1111/j.1365-2133.2009.09216.x

M3 - Article

C2 - 19438432

VL - 161

SP - 419

EP - 426

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 2

ER -